InVivo Therapeutics Announces New Responsibilities for Senior Management
Team Members

June 24, 2014 04:30 PM Eastern Daylight Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the
expansion of responsibilities for three members of its senior management
team. The additional functional responsibilities, now at the senior
management level, include Operations, Project Management, and
Reimbursement Planning.

William D’Agostino, PE has been appointed Senior Vice President,
Operations. Prior to his new responsibilities, he held the position of
Vice President, Manufacturing & Engineering. Bill joined InVivo in
September 2012. Previously, he held the position of Vice President,
Engineering at Angiotech Pharmaceuticals which included running all
product development and engineering activities across their
international facilities. Bill also worked for Covidien for fifteen
years where he gained extensive experience with the development,
synthesis and clinical production of bioabsorbable polymers. He is a
co-author of the book, Regulatory Strategies for Combination Products,
published by PDA and DHI Publishing. Bill holds fourteen US and European
patents for medical devices on which he co-invented. Bill is a Licensed
Professional Engineer (PE) and holds an MBA from the University of
Dallas and a BS in both Chemical Engineering and Materials Engineering
from the University of Connecticut.

Kristin Neff has been appointed Vice President, Clinical Operations &
Project Management. Previously, she held the position of Vice President,
Clinical Operations. Kristin joined InVivo in August 2013 from TARIS
Biomedical where she served as Senior Director, Clinical Operations.
Prior to that, she was Vice President, Clinical Affairs at ConforMIS,
Inc. and Director of Clinical Project Management at HeartWare, Inc.
Kristin has an MS in Biomedical Engineering from Boston University and a
BS in Electrical Engineering from UMass, Amherst. Kristin is a noted
presenter at many conferences including Clinical Trials New England,
Project Management Institute, Drug Information Association, and more.

Lisa Crockett has been appointed Vice President, Regulatory Affairs &
Reimbursement Planning. Previously, she held the position of Vice
President, Regulatory Affairs. Lisa joined InVivo in June of 2013 from
Genzyme, where she most recently served as Associate Director of
Regulatory Affairs. Lisa holds an MS in Regulatory Affairs from
Northeastern University and a BS from Johnson and Wales University. Lisa
is a part-time instructor in the Master’s Degree Program in Regulatory
Affairs at Northeastern University.

All three members of the senior management team will report to CEO, Mark
Perrin. Regarding these changes, Mark stated, “Following yesterday’s
announcement of our new research and development strategy and the future
direction of the company, it is critical to have these key functional
responsibilities at the senior management level. Recognizing the
valuable contributions that have been made by these three individuals,
it is gratifying to have them assume such important additional
responsibilities and is yet another example of the building and
strengthening of our leadership team.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and
biotechnology company with a focus on treatment of spinal cord injuries.
The company was founded in 2005 with proprietary technology co-invented
by Robert Langer, ScD., Professor at Massachusetts Institute of
Technology, and Joseph P. Vacanti, M.D., who is affiliated with
Massachusetts General Hospital. In 2011 the Company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. The publicly
traded company is headquartered in Cambridge, MA. For more details,
visit www.invivotherapeutics.com.